Abstract
Intraovarian platelet-rich plasma (PRP) infusion was recently introduced in the context of addressing ovarian insufficiency. Reporting on its effectiveness prior to adopting in clinical routine practice is imperative. This study aims to provide pilot data regarding PRP application for ovarian rejuvenation. Four pilot studies were conducted on poor ovarian response (POR), premature ovarian insufficiency (POI), perimenopause, and menopause, respectively. Each pilot study reports on thirty patients, 120 participants were recruited in total. All participants provided written informed consent prior to treatment. Primary outcome measures for the POR pilot study were levels of anti-müllerian hormone (AMH), antral follicle count (AFC) and oocyte yield. For the POI, perimenopausal and menopausal pilot studies primary outcome measures were restoration of menstrual cycle, and Follicle Stimulating Hormone (FSH) levels. A significant improvement on the hormonal profile and the ovarian reserve status was noted, along with improved intracytoplasmic sperm injection (ICSI) cycle performance concerning POR participants. Menstruation recovery was observed in 18 out of 30 POI patients, along with a statistically significant improvement on levels of AMH, FSH, and AFC. Similarly, 13 out of 30 menopausal women positively responded to PRP treatment. Finally, menstruation regularity, improved hormonal levels and AFC were reported for 24 out of 30 perimenopausal women. To conclude, PRP infusion appears to convey promising results in addressing ovarian insufficiency.
Highlights
Clinicians are often called to address the challenging issue of ovarian insufficiency in the context of fertility treatment [1]
Thirteen women (43.3%) positively responded to platelet-rich plasma (PRP) treatment, constituting what is described as the PRP success subgroup for this pilot study
Regarding the PRP success subgroup, antral follicle count (AFC) along with anti-müllerian hormone (AMH), Follicle Stimulating Hormone (FSH), luteinizing hormone (LH) and E2 presented statistically significantly improved from the first month of the follow-up post PRP treatment
Summary
The POSEIDON (Patient-Oriented Strategies Encompassing Individualized Oocyte Number) group proposed a new stratification employing a respective developed algorithm to categorize patients based on qualitative and quantitative parameters: (a) maternal age and the expected aneuploidy rate, (b) ovarian reserve biomarker levels such as antral follicle count (AFC) and anti-müllerian hormone (AMH), and c) ovarian response data in previous cycles following ovarian stimulation protocols. This approach offers a practical endpoint to clinicians by assisting in setting a clear goal for management of the group of “low prognosis patients” in assisted reproduction treatment (ART) [8,9]. Of the definition, POR women commonly present with scarcity of stimulable follicles resulting in low oocyte yield, and high cancellation rates following ART [8]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
